The combination effect of oncolytic viral therapy has been explored by Saha et al., who investigated the effects of combining a PD-L1 antibody with an anti-CTLA-4 treatment and an oncolytic herpes simplex virus in a mouse model of glioma. This evidence concerns the gene CTLA4 and glioma.